Health Economics›Gastric cancer›Perioperative therapy

Perioperative therapy

Gastric cancer · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FLOT Variant #03	—	R 7 216	21d	—	50.0 mo	—	—	1
DOX-CapeOx Variant #01	—	R 5 438	21d	—	—	—	—	—
ECF Variant #04	—	R 3 931	21d	—	48.0 mo	—	—	2
EOX Variant #01	—	R 3 411	21d	—	48.0 mo	—	—	1
EOF Variant #01	—	R 3 063	21d	—	48.0 mo	—	—	1
mFOLFOX6 Variant #02	—	R 2 466	14d	~7.6 mo	~12.2 mo	~17	~R 41 930 PFS proxy · indirect	4
CapeOx Variant #01	—	R 2 384	21d	~6.5 mo	~12.2 mo	~10	~R 23 842 PFS proxy · indirect	16
ECX Variant #01	—	R 2 313	21d	—	48.0 mo	—	—	1
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	—	55.7 mo	—	—	2
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 386	21d	—	55.7 mo	—	—	1
SOX Variant #01 Partial	—	R 1 075	21d	~5.6 mo	—	~9	~R 9 677 PFS proxy · indirect	2

11 of 11 regimens shown